Table 1 Intergroup comparison of standard-of-care baseline clinicopathological predictors of prostate cancer progression in patients enrolled on active surveillance.
Baseline predictor | Progressors (n = 34) | Non-progressors (n = 37) | p-value |
|---|---|---|---|
Median (IQR) | |||
PSA, ng/mL | 7.0 (4.9–8.7) | 4.9 (3.4–6.8) | 0.021 |
Gland-volume, mL | 45.0 (32.0–53.0) | 44.8 (35.8–66.5) | 0.329 |
PSA density | 0.17 (0.10–0.22) | 0.09 (0.06–0.15) | 0.003 |
Likert score | 4.0 (4.0–5.0) | 4.0 (4.0–5.0) | 0.532 |
Biopsy grade group 1 (3 + 3 = 6) | 26 | 28 | – |
Biopsy grade group 2 (3 + 4 = 7) | 8 | 10 | |
Target lesion in the peripheral zone | 23 | 29 | – |
Target lesion in the transition zone | 12 | 9 | |
